Guide contents
Open in calculatorCompound briefing
Retatrutide (LY-3437943) is a novel single-molecule triple receptor agonist developed by Eli Lilly, currently in Phase 3 trials. Unlike semaglutide (GLP-1) or tirzepatide (GLP-1/GIP), retatrutide also activates the glucagon receptor — adding hepatic fat oxidation, thermogenesis and energy-expenditure mechanisms absent from prior-generation agents.
The research question
Retatrutide adds glucagon-receptor activity to dual-incretin signalling. Researchers are therefore measuring not only intake and glycaemia, but also energy expenditure, hepatic fat and the tolerability consequences of engaging three receptors at once.
Mechanism & research themes
Balanced agonism of GIP (incretin effect and adipocyte lipid metabolism), GLP-1 (satiety, insulin secretion, delayed gastric emptying) and glucagon (hepatic fat oxidation, thermogenesis, basal metabolic rate). The glucagon arm is uniquely responsible for elevated energy expenditure vs GLP-1/GIP duals.
24.2% mean body weight reduction at 12mg/week over 48 weeks (Phase 2, NEJM 2023)
approximately 32kg average weight loss reported in TRIUMPH-4 Phase 3 (Dec 2025)
HbA1c reduction of 1.7–2.0% in TRIUMPH-T2D (Mar 2026)
Significant hepatic fat fraction reduction — NASH indication under investigation
Improvements across triglycerides, LDL and blood pressure
Elevated basal metabolic rate via glucagon-receptor thermogenesis
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Randomised human trials provide meaningful efficacy and safety data, but the evidence base is younger than that of established GLP-1 medicines. Long-term outcomes remain an active research question.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Phase 2/3 escalation: 2mg weekly (weeks 1–4) → 4mg (weeks 5–8) → 8mg (weeks 9–12) → maintenance at 8mg or 12mg weekly based on tolerability. Subcutaneous (abdomen, thigh or upper arm). Not FDA-approved — research use only.
Reported persistence
approximately 144 hours (approximately 6 days), enabling once-weekly dosing.
Calculator starting point
2 mg per reference dose
1 doses per week · 12-week cycle
2 mL default reconstitution volume
Phase 2 escalation: 2 → 4 → 8 mg weekly; maintenance 8–12 mg/week.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate RetatrutideLaboratory handling
Reconstitution reference
Select the water volume from the target concentration: a 10mg vial with 2mL bacteriostatic water gives 5mg/mL. Add the water slowly down the side of the vial and swirl gently — do not agitate vigorously.
Storage reference
Lyophilised: 2–8°C (stable 24–36 months); avoid freeze-thaw cycling. Reconstituted: 2–8°C, do not freeze, use within 28 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
GI events (approximately 60% rate at therapeutic doses in Phase 2) — class effect amplified by glucagon component, dose-limiting at escalation.
Modest resting heart-rate elevation (+2–4 BPM) — a distinguishing safety signal vs pure GLP-1 agents.
No long-term human safety dataset yet; post-market signals remain open questions.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading